GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Epigral Ltd (NSE:EPIGRAL) » Definitions » Revenue

Epigral (NSE:EPIGRAL) Revenue : ₹19,292 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Epigral Revenue?

Epigral's revenue for the three months ended in Mar. 2024 was ₹5,246 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2024 was ₹19,292 Mil. Epigral's Revenue per Share for the three months ended in Mar. 2024 was ₹126.30. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was ₹464.21.

Warning Sign:

Epigral Ltd revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Epigral was -11.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 48.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was 32.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 7 years, Epigral's highest 3-Year average Revenue per Share Growth Rate was 53.10% per year. The lowest was -0.50% per year. And the median was 39.15% per year.


Epigral Revenue Historical Data

The historical data trend for Epigral's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigral Revenue Chart

Epigral Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Revenue
Get a 7-Day Free Trial 6,101.72 8,259.37 15,509.41 21,884.00 19,291.92

Epigral Quarterly Data
Mar18 Mar19 Mar20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,621.77 4,548.92 4,781.46 4,715.20 5,246.33

Competitive Comparison of Epigral's Revenue

For the Chemicals subindustry, Epigral's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epigral's Revenue Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, Epigral's Revenue distribution charts can be found below:

* The bar in red indicates where Epigral's Revenue falls into.



Epigral Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹19,292 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Epigral  (NSE:EPIGRAL) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Epigral Revenue Related Terms

Thank you for viewing the detailed overview of Epigral's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Epigral (NSE:EPIGRAL) Business Description

Traded in Other Exchanges
Address
Corporate Road, 5th Floor, 6th Floor & 7th Floor, Meghmani House, Behind Safal Profitaire, Prahladnagar, Ahmedabad, GJ, IND, 380015
Epigral Ltd Formerly Meghmani Finechem Ltd is a producer of Chlor-Alkali and its Derivatives and specialty chemicals with backward and forward integration facilities. It manufactures Caustic Soda, Caustic Potash, CPVC Resin, Epichlorohydrin, Chlorine, Hydrogen, Chloromethanes, and Hydrogen Peroxide. The company is focused on servicing domestic as well as international markets.

Epigral (NSE:EPIGRAL) Headlines

No Headlines